Search Result

Results for "

mobilization

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Adrenergic Receptor (1) Apoptosis (3) Aryl Hydrocarbon Receptor (1) Bombesin Receptor (1) Calcium Channel (8) Cannabinoid Receptor (1) CCR (4) Complement System (2) CXCR (8) Dopamine Receptor (1) EBI2/GPR183 (3) Endogenous Metabolite (6) ERK (1) Estrogen Receptor/ERR (1) Fluorescent Dye (1) Formyl Peptide Receptor (FPR) (2) Free Fatty Acid Receptor (1) GHSR (2) GPR84 (2) HIV (1) Integrin (3) Interleukin Related (1) JNK (1) Leukotriene Receptor (3) LPL Receptor (1) mAChR (4) MCHR1 (GPR24) (2) Melanocortin Receptor (3) mGluR (11) Na+/K+ ATPase (1) nAChR (1) Neurokinin Receptor (1) Neuropeptide Y Receptor (3) Neurotensin Receptor (1) Opioid Receptor (1) P2Y Receptor (1) Parasite (1) PERK (1) Prostaglandin Receptor (2) Protease Activated Receptor (PAR) (1) Reactive Oxygen Species (1) TRP Channel (2) Urotensin Receptor (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (9) Endocrinology (12) Infection (5) Inflammation/Immunology (36) Metabolic Disease (16) Neurological Disease (36)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153132

mGluR3 modulator-1	mGluR	Metabolic Disease
mGluR3 modulator-1 (compound 3) is a mGluR3 modulator, with an EC₅₀ of 1-10 μM in HEK293T-mGluR-Gqi5 Calcium Mobilization Assay .

HY-103572

MNI137	mGluR	Neurological Disease
MNI137 is a potent and selective negative allosteric modulator for group II mGluRs. MNI137 has IC₅₀s values of 8.3 and 12.6 nM for human and rat mGlu2 inhibition of glutamate-induced calcium mobilization .

HY-A0231

Glymidine sodium Gondafon; Glycodiazine	Others	Metabolic Disease
Glymidine sodium is an oral active antidiabetic. Glymidine sodium is the inhibitor of hepatic lipolysis. Glymidine sodium inhibits the glucose formation and supresses the elevated pyruvate oxidation which results from the inhibition of endogenous lipid mobilization .

HY-107589A

BIO5192 hydrate 1 Publications Verification	Integrin	Inflammation/Immunology
BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (K_d<10 pM). BIO5192 hydrate selectively binds to α4β1 (IC₅₀=1.8 nM) over a range of other integrins. BIO5192 hydrate results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .

HY-I0466

Glutarimide	Others	Others
Glutarimide is a typical glutarimide-related compound, which has an effect on Carbachol (HY-B1208) induced Ca ²⁺ mobilization with an IC₅₀ value of >120 μM .

HY-144347

HF51116	CXCR	Infection Cancer
HF51116 is a potent antagonist of CXCR4. HF51116 strongly antagonizes SDF-1α-induced cell migration, calcium mobilization, and CXCR4 internalization. HF51116 inhibits HIV-1 infection via CXCR4. HF51116 has the potential for the research of HIV-1 infection, hematopoietic stem cell mobilization, and cancer metastasis .

HY-101607A

KT-362 free acid	Calcium Channel	Cardiovascular Disease
KT-362 free acid is an intracellular calcium antagonist with antiarrhythmic and vasodilatory effects. KT-362 free acid shows an antagonistic effect against norepinephrine (NE) induced vasoconstriction response, achieved by reducing inositol phospholipid hydrolysis, thereby reducing intracellular calcium mobilization. KT-362 free acid can be used to study the contraction and relaxation mechanisms of vascular smooth muscle, especially in exploring the role of intracellular calcium mobilization and inositol phospholipid hydrolysis in vascular contraction .

HY-130704

Isotachysterol 3	Calcium Channel	Metabolic Disease
Isotachysterol 3 is an analog of 1,25-dihydrox Vitamin D3. Isotachysterol 3 stimulates intestinal calcium transport and bone calcium mobilization in anephric rats .

HY-112741

SB-209247	Leukotriene Receptor	Inflammation/Immunology
SB-209247 is a selective, high affinity and orally active leukotriene B4 (LTB4) receptor antagonist with a K_i of 0.78 nM. SB-209247 blocks LTB4-induced Ca ²⁺ mobilization with an IC₅₀ of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity .

HY-P5756

CSD-CH2(1,8)-NH2	Opioid Receptor	Neurological Disease
CSD-CH2(1,8)-NH2 is a selective and competitive KOR antagonist (K_i: 6.8 nM). CSD-CH2(1,8)-NH2 inhibits calcium mobilization in DRG neurons. CH2(1,8)-NH2 antagonizes the antinociceptive effect of U50,488. CSD-CH2(1,8)-NH2 can be used for research of neuropsychiatric disorders .

HY-107589

BIO5192 1 Publications Verification	Integrin	Inflammation/Immunology
BIO5192 is a selective and potent integrin α4β1 (VLA-4) inhibitor (K_d<10 pM). BIO5192 selectively binds to α4β1 (IC₅₀=1.8 nM) over a range of other integrins. BIO5192 results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .

HY-129808

VPC12249	Others	Cardiovascular Disease Cancer
VPC12249 is a competitive dual LPA1/LPA3 antagonist with K_i values of 137nM and 428 nM, respectively. VPC12249 inhibits calcium mobilization in HEK293T cells with a K_i value of ~130 nM. VPC12249 is promising for research of ovarian cancer and hypertensive diseases .

HY-145697

GPR84 antagonist 2	GPR84	Inflammation/Immunology
GPR84 antagonist 2 (compound 33) is a potent, selective, and orally active GPR84 antagonist (IC₅₀=8.95 nM). GPR84 antagonist 2 shows improved potency in the calcium mobilization assay and the ability to inhibit the chemotaxis of neutrophils and macrophages upon GPR84 activation. GPR84 antagonist 2 has the potential for the research of ulcerative colitis .

HY-129453

BOP sodium	Integrin	Inflammation/Immunology
BOP sodium is a potent and selective dual α9β1/α4β1 integrin inhibitor with K_d values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors. BOP sodium has little inhibitory activity on α4β7, α1β1, α2β1, and α5β1, αIIBβ3 integrins .

HY-163796

GPR183-IN-2	EBI2/GPR183	Neurological Disease Inflammation/Immunology Cancer
GPR183-IN-2 (compound 23) is a potent GPR183 inhibitor. GPR183-IN-2 inhibits Ca ²⁺ mobilization with an IC₅₀ value of 39.45 nM. GPR183-IN-2 has the potential for the research of cancer, autoimmune diseases, pain, and osteoporosis .

HY-163795

GPR183-IN-1	EBI2/GPR183	Neurological Disease Inflammation/Immunology Cancer
GPR183-IN-1 (compound 15) is a potent and orally activity GPR183 inhibitor. GPR183-IN-1 inhibits Ca ²⁺ mobilization with an IC₅₀ value of 39.97 nM. GPR183-IN-1 has the potential for the research of cancer, autoimmune diseases, pain, and osteoporosis .

HY-116723

CFMMC	mGluR	Neurological Disease
CFMMC is a selective allosteric metabotropic glutamate receptor 1 (mGluR1) antagonist. CFMMC inhibits L-glutamate-induced intracellular Ca ²⁺ mobilization ([Ca ²⁺]i) in Chinese hamster ovary cells expressing recombinant human mGluR1a with an IC₅₀ value of 50 nM. CFMMC is promising for research of various central nervous system disorders, such as schizophrenia, epilepsy, anxiety, pain, cognitive dysfunction and drug abuse .

HY-16992A

W-54011 5 Publications Verification	Complement System Reactive Oxygen Species	Inflammation/Immunology
W-54011 is a potent and orally active non-peptide C5a receptor antagonist. W-54011 inhibits the binding of ¹²⁵I-labeled C5a to human neutrophils with a K_i value of 2.2 nM. W-54011 also inhibits C5a-induced intracellular Ca ²⁺ mobilization, chemotaxis, and generation of ROS in human neutrophils with IC₅₀s of 3.1 nM, 2.7 nM, and 1.6 nM, respectively .

HY-19434

trans-ACPD Trans-(±)-ACP	mGluR	Metabolic Disease
trans-ACPD, a metabotropic receptor agonist, produces calcium mobilization and an inward current in cultured cerebellar Purkinje neurons.

HY-P1250

RFRP-3(human) Neuropeptide VF(124-131)(human)	Neuropeptide Y Receptor	Neurological Disease
RFRP-3 (Neuropeptide VF(124-131))(human), a human GnIH peptide homolog, is a potent inhibitor of gonadotropin secretion by inhibiting Ca ²⁺?mobilization. RFRP-3(human) is a NPFF1?receptor agonist, it inhibits forskolin-induced production of cAMP with an IC₅₀ of 0.7 nM .

HY-P1250A

RFRP-3(human) TFA Neuropeptide VF(124-131)(human) TFA	Neuropeptide Y Receptor	Neurological Disease
RFRP-3 (Neuropeptide VF(124-131))(human) TFA, a human GnIH peptide homolog, is a potent inhibitor of gonadotropin secretion by inhibiting Ca ²⁺?mobilization. RFRP-3(human) is a NPFF1?receptor agonist, it inhibits forskolin-induced production of cAMP with an IC₅₀ of 0.7 nM .

HY-139646

KMG-104	Fluorescent Dye	Neurological Disease
KMG-104 is a highly selective fluorescent Mg ²⁺ probe. KMG-104 has been used widely and revealed Mg ²⁺ mobilization in cytoplasm in various types of cells .

HY-16639

ML314	Neurotensin Receptor	Neurological Disease Endocrinology
ML314 is a potent molecule agonist of NTR1 (EC₅₀ = 1.9 μM); showed good selectivity against NTR2 and GPR35, but does not stimulate Ca ²⁺ mobilization.

HY-100402

CFMTI	mGluR	Cancer
CFMTI inhibits L-glutamate-induced intracellular Ca ²⁺ mobilization in CHO cells expressing human and rat mGluR1a, with IC₅₀s of 2.6 and 2.3 nM, respectively .

HY-111332

(E)-PHCCC	mGluR	Others
(E)-PHCCC is a positive allosteric modulator (PAM) for mGluR4, that enhances the activity of the receptor's endogenous ligand (glutamate), and exhibits activity in the calcium mobilization assay in CHO cells with an EC₅₀ of 3.2 μM .

HY-125088

Oleoylestrone	Others	Others
Oleoyl-estrone (OE) is a signaling molecule derived from adipose tissue that reduces energy intake and body fat while maintaining energy expenditure and blood glucose balance. In studies in adrenalodepleted female rats, administration of OE resulted in significant fat mobilization, reduced food intake, and sustained energy expenditure. However, concomitant administration of corticosterone inhibits OE-induced fat mobilization and aggravates insulin resistance and glycemic imbalance by promoting fat deposition. This suggests that corticosterone has an antagonistic effect on the beneficial metabolic effects of OE, particularly on lipid metabolism and insulin sensitivity .

HY-B0499A

Otilonium bromide 2 Publications Verification Octylonium bromide; SP63	mAChR	Neurological Disease
Otilonium bromide (OB) is an orally active mAChR inhibitor and smooth muscle relaxant which can interfere with the mobilization of calcium in intestinal smooth muscle, OB can be used for research of irritable bowel syndrome .

HY-125717

VU0029251	mGluR	Neurological Disease
VU0029251 is a mGluR5 partial antagonist (K_i: 1.07 μM). VU0029251 inhibits glutamate induced calcium mobilization in HEK293 cell membranes expressing rat mGluR5 (IC₅₀: 1.7 μM) .

HY-123763

MLN3126	CCR	Inflammation/Immunology
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC₅₀ value of 6.3 nM for calcium influx .

HY-P1121A

WKYMVM-NH2 TFA	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase .

HY-144784

CXCR2 antagonist 7	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 7 (compound 19) is a potent CXCR2 antagonist. CXCR2 antagonist 7 shows potent CXCR2 binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM) ^{[ 1]}.

HY-144781

CXCR2 antagonist 5	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 5 (compound 25) is a potent CXCR2 antagonist. CXCR2 antagonist 5 shows potent CXCR2 binding affinity (IC₅₀=0.013 µM) and calcium mobilization (IC₅₀=0.1 µM) ^{[ 1]}.

HY-144783

CXCR2 antagonist 6	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 6 (compound 35c) is a potent CXCR2 antagonist. CXCR2 antagonist 6 shows potent CXCR2 binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM) ^{[ 1]}.

HY-103472

FPR-A14	Formyl Peptide Receptor (FPR)	Neurological Disease
FPR-A14 is a potent formyl peptide receptor (FPR) agonist. FPR-A14 is a potent activator of neutrophil Ca ²⁺ mobilization and chemotaxis with EC₅₀s of 630 nM and 42 nM, respectively. FPR-A14 induces cell differentiation .

HY-10656

SB-657510	Urotensin Receptor	Inflammation/Immunology
SB-657510 is a selective urotensin II (UII) receptor (UT) antagonist. The K_i values are 61, 17, 30, 65 and 56 nM for human, monkey, cat, rat and mouse receptors, respectively. SB-657510 exerts anti-inflammatory effects by inhibiting UII-induced upregulation of inflammatory mediators such as adhesion molecules, cytokines, and tissue factor in human vascular endothelial cells .

HY-118806

AC-42	mAChR	Neurological Disease
AC-42 is a poent M1 muscarinic selective allosteric agonist with EC₅₀s of 805 nM and 220 nM for human wild-type and Y381A mutated M1 receptors, respectively. AC-42 stimulates the IP-accumulation and calcium mobilization in CHO cells .

HY-13628A

Etalocib sodium LY293111 sodium; VML 295 sodium	Leukotriene Receptor Apoptosis	Inflammation/Immunology Cancer
Etalocib (LY293111) sodium, an orally active leukotriene B₄ receptor antagonist, inhibits the binding of [ ³H]LTB₄, with a K_i of 25 nM. Etalocib sodium prevents LTB₄-induced calcium mobilization with an lC₅₀ of 20 nM. Etalocib sodium induces apoptosis .

HY-50688

SB-265610 2 Publications Verification	CXCR	Inflammation/Immunology
SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC₅₀s of 3.7 nM and 70 nM, respectively .

HY-114978

VU0424465	mGluR PERK	Neurological Disease
VU0424465 is a potent and partial PAM (positive allosteric modulator)-agonist for mGlu₅ mediated iCa ²⁺ mobilization. VU0424465 exhibits high affinity at MPEP allosteric binding site, with a K_i value of 11.8 nM. VU0424465 is also a agonist for pERK1/2 in cortical neurons .

HY-147301

Resomelagon AP1189	Melanocortin Receptor	Metabolic Disease Inflammation/Immunology
Resomelagon (AP1189) is a potent, orally active melanocortin receptor (MR) agonist about MC₁ and MC₃. Resomelagon induces ERK1/2 phosphorylation and Ca ²⁺ mobilization. Resomelagon has anti-inflammatory activity. Resomelagon can be used for obesity and chronic inflammation research .

HY-147301A

Resomelagon acetate AP1189 acetate	Melanocortin Receptor	Metabolic Disease Inflammation/Immunology
Resomelagon (AP1189) acetate is a potent, orally active melanocortin receptor (MR) agonist about MC₁ and MC₃. Resomelagon acetate induces ERK1/2 phosphorylation and Ca ²⁺ mobilization. Resomelagon acetate has anti-inflammatory activity. Resomelagon acetate can be used for obesity and chronic inflammation research .

HY-129851

NTP42	Prostaglandin Receptor	Cardiovascular Disease
NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC₅₀ of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca ²⁺] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .

HY-N7395

Cyclic ADP-ribose cADPR	Calcium Channel TRP Channel Endogenous Metabolite	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology
Cyclic ADP-ribose (cADPR) is a potent second messenger for calcium mobilization that is synthesized from NAD ⁺ by an ADP-ribosyl cyclase. Cyclic ADP-ribose increases cytosolic calcium mainly by Ryanodine receptor-mediated release from endoplasmic reticulum and also by extracellular influx through the opening of TRPM2 channels .

HY-13628

Etalocib 1 Publications Verification LY293111; VML 295	Leukotriene Receptor Apoptosis	Inflammation/Immunology Cancer
Etalocib (LY293111), an orally active leukotriene B₄ receptor antagonist, inhibits the binding of [ ³H]LTB₄, with a K_i of 25 nM. Etalocib (LY293111) prevents LTB₄-induced calcium mobilization with an lC₅₀ of 20 nM. Etalocib (LY293111) induces apoptosis .

HY-B0499AR

Otilonium bromide (Standard)	mAChR	Neurological Disease
Otilonium (bromide) (Standard) is the analytical standard of Otilonium (bromide). This product is intended for research and analytical applications. Otilonium bromide (OB) is an orally active mAChR inhibitor and smooth muscle relaxant which can interfere with the mobilization of calcium in intestinal smooth muscle, OB can be used for research of irritable bowel syndrome .

HY-P1437A

Neuropeptide S(Mouse) TFA	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide S(Mouse) TFA is a potent endogenous neuropeptide S receptor (NPSR) agonist (EC₅₀=3 nM). Neuropeptide S(Mouse) TFA induces mobilization of intracellular Ca ²⁺. Neuropeptide S(Mouse) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Mouse) TFA also reduces anxiety-like behavior in mice.

HY-N7395A

Cyclic ADP-ribose ammonium cADPR ammonium	Calcium Channel TRP Channel Endogenous Metabolite	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology
Cyclic ADP-ribose ammonium (cADPR ammonium) is a potent second messenger for calcium mobilization that is synthesized from NAD ⁺ by an ADP-ribosyl cyclase. Cyclic ADP-ribose ammonium increases cytosolic calcium mainly by Ryanodine receptor-mediated release from endoplasmic reticulum and also by extracellular influx through the opening of TRPM2 channels .

HY-146413

HF50731	CXCR HIV	Infection Cancer
HF50731 (compound 21) is a potent CXCR4 antagonist. HF50731 shows strong CXCR4 binding affinity, with IC₅₀ of 19.8 nM. HF50731 effectively inhibits calcium mobilization, cell migration, and HIV-1 infection via CXCR4 coreceptor, with IC₅₀ values of 119.2 nM, 621.4 nM and 1.5 μM .

HY-147222

SAE-14 1 Publications Verification GPR183 antagonist-1	EBI2/GPR183	Neurological Disease Inflammation/Immunology
SAE-14 (compound SAE-14) is a potent, specific GPR183 antagonist with an IC₅₀ value of 28.5 nM, can antagonize 7α, 25-OHC–induced calcium mobilization with IC₅₀ value below 50 nM in HL-60 cells. GPR183 antagonist-1 can reverse allodynia in mice .

HY-124404

12(R)-HETE	Na+/K+ ATPase Aryl Hydrocarbon Receptor	Others Inflammation/Immunology
12(R)-HETE is a metabolite of Arachidonic acid, AA (HY-109590) and can be found in skin from psoriatic lesions. 12(R)-HETE induces lymphocytes chemotaxis, stimulates calcium mobilization and chemotaxis in neutrophils via the BLT1 receptor, activates the aryl hydrocarbon receptor, and inhibits Na+/K+ ATPase activity in the corneal epithelium .

Cat. No.	Product Name	Type

HY-W339833

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium

Cell Assay Reagents

1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium is a kind of activity that promotes platelet aggregation and stimulates smooth muscle contraction. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can enhance cell chemotaxis and cytoskeletal rearrangement. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium can also promote Ca2+ mobilization and neurotransmitter release. 1-Myristoyl-2-hydroxy-sn-glycero-3-phosphate sodium also has a certain effect on cell proliferation.

Cat. No.	Product Name	Target	Research Area

HY-P1250

RFRP-3(human) Neuropeptide VF(124-131)(human)	Neuropeptide Y Receptor	Neurological Disease
RFRP-3 (Neuropeptide VF(124-131))(human), a human GnIH peptide homolog, is a potent inhibitor of gonadotropin secretion by inhibiting Ca ²⁺?mobilization. RFRP-3(human) is a NPFF1?receptor agonist, it inhibits forskolin-induced production of cAMP with an IC₅₀ of 0.7 nM .

HY-P1121A

WKYMVM-NH2 TFA	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase .

HY-P3789

Prolactin-Releasing Peptide (12-31), rat	Peptides	Metabolic Disease
Prolactin-Releasing Peptide (12-31), rat is a fragment of the prolactin releasing peptide (PrRP). Prolactin-Releasing Peptide (12-31), rat shows high affinity for GPR10 receptors. Prolactin-Releasing Peptide (12-31), stimulates calcium mobilization in CHOK1 cells transfected with the PrRP receptor .

HY-P0172A

ATI-2341 TFA 2 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-P5756

CSD-CH2(1,8)-NH2	Opioid Receptor	Neurological Disease
CSD-CH2(1,8)-NH2 is a selective and competitive KOR antagonist (K_i: 6.8 nM). CSD-CH2(1,8)-NH2 inhibits calcium mobilization in DRG neurons. CH2(1,8)-NH2 antagonizes the antinociceptive effect of U50,488. CSD-CH2(1,8)-NH2 can be used for research of neuropsychiatric disorders .

HY-P1250A

RFRP-3(human) TFA Neuropeptide VF(124-131)(human) TFA	Neuropeptide Y Receptor	Neurological Disease
RFRP-3 (Neuropeptide VF(124-131))(human) TFA, a human GnIH peptide homolog, is a potent inhibitor of gonadotropin secretion by inhibiting Ca ²⁺?mobilization. RFRP-3(human) is a NPFF1?receptor agonist, it inhibits forskolin-induced production of cAMP with an IC₅₀ of 0.7 nM .

HY-P1437A

Neuropeptide S(Mouse) TFA	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide S(Mouse) TFA is a potent endogenous neuropeptide S receptor (NPSR) agonist (EC₅₀=3 nM). Neuropeptide S(Mouse) TFA induces mobilization of intracellular Ca ²⁺. Neuropeptide S(Mouse) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Mouse) TFA also reduces anxiety-like behavior in mice.

HY-P3570

Adipokinetic hormone II (Locusta migratoria) Lom-AKH-II	Endogenous Metabolite	Metabolic Disease
Adipokinetic hormone II (Locusta migratoria) (Lom-AKH-II) is a insect adipokinetic hormone (AKH), enhances fat body cAMP levels in vitro. Insect adipokinetic hormones (AKHs) controls flight-directed mobilization of carbohydrate and lipid from fat body stores, which depends on AKH receptor(s) coupling to cAMP formation and glycogen phosphorylase activation via the stimulatory guanine nucleotide-binding protein (Gs) .

HY-P3572

Adipokinetic hormone I (Locusta migratoria) Lom-AKH-I	Endogenous Metabolite	Endocrinology
Adipokinetic hormone I (Locusta migratoria) (Lom-AKH-I) is a insect adipokinetic hormone (AKH), enhances fat body cAMP levels in vitro. Insect adipokinetic hormones (AKHs) controls flight-directed mobilization of carbohydrate and lipid from fat body stores, which depends on AKH receptor(s) coupling to cAMP formation and glycogen phosphorylase activation via the stimulatory guanine nucleotide-binding protein (Gs) .

HY-P1205

MCH(human, mouse, rat) Melanin-concentrating hormone(human, mouse, rat)	MCHR1 (GPR24)	Neurological Disease
MCH (human, mouse, rat) is a potent peptide agonist of MCH-R and exhibits binding IC₅₀ values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHO cell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC₅₀ values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively .

HY-P0172

ATI-2341	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-P1205A

MCH(human, mouse, rat) TFA 1 Publications Verification Melanin-concentrating hormone(human, mouse, rat) TFA	MCHR1 (GPR24)	Neurological Disease
MCH (human, mouse, rat) TFA is a potent peptide agonist of MCH-R and exhibits binding IC₅₀ values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHO cell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC₅₀ values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively .

HY-P2055

A-57696	Peptides	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

HY-103544

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P	JNK Interleukin Related Bombesin Receptor	Inflammation/Immunology Cancer
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8 and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca ²⁺ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a bombesin antagonist, and inhibits the growth of small cell lung cancer

Cat. No.	Product Name		Classification

HY-W783254

C18 LPA PA(18:0e/0:0)		Phospholipids
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks